Pronunciation: RYE–breh–vant
Generic name: amivantamab-vmjw
Dosage form: injection for intravenous infusion (350 mg/7 mL)
Drug class: Miscellaneous bispecific antibodies

Medically reviewed by Carmen Pope, BPharm. Last updated on Jun 26, 2025.

What is Rybrevant?

Rybrevant is used to treat advanced non-small cell lung cancer (NSCLC) in adults that has certain EGFR mutations and has metastasized or cannot be removed by surgery. It is given by IV infusion every 1 to 3 weeks.

Rybrevant works by targeting two specific proteins on cancer cells: EGFR and MET. It binds to both proteins simultaneously, blocking the growth signals they normally send to help tumors proliferate. Rybrevant works particularly well against lung cancers with specific EGFR mutations, including exon 19 deletions, L858R substitutions, and exon 20 insertions. Once bound, it either prevents these proteins from functioning or triggers their degradation. Additionally, when Rybrevant attaches to tumor cells, it marks them for destruction by immune cells like natural killer cells and macrophages through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis. Studies show that combining Rybrevant with lazertinib produces stronger anti-tumor effects than either drug alone, making it an effective treatment approach for EGFR-mutated non-small cell lung cancer. It belongs to the drug class called bispecific antibodies.

Rybrevant is a targeted treatment and is not chemotherapy, although it may be used with chemotherapy.  

Rybrevant (amivantamab) gained FDA approval on May 21, 2021, and is made by Janssen Biotech. There is no generic or biosimilar. Approval for Rybrevant in NSCLC was based on positive results from the following clinical trials:

• MARIPOSA (858 patients with exon 19 deletions or exon 21 L858R EGFR mutations; NCT04487080) Rybrevant + Lazcluze showed 30% lower risk of disease progression versus osimertinib (median PFS 23.7 vs 16.6 months) and 25% lower death risk in patients receiving first-line treatment.
• MARIPOSA-2 (NCT04988295) Rybrevant + chemotherapy reduced disease progression risk by 52% versus chemotherapy alone in 394 second-line EGFR-mutated NSCLC patients. Median PFS was 6.3 versus 4.2 months, with 53% versus 29% response rates.
• PAPILLON (308 patients with EGFR exon 20 insertion mutations; NCT04538664) Rybrevant + chemotherapy reduced disease progression risk by 60% versus chemotherapy alone. Median progression-free survival was 11.4 months versus 6.7 months, with 67% versus 37% response rates respectively.
• CHRYSALIS (NCT02609776), Rybrevant achieved a 40% overall response rate in 81 EGFR exon 20 insertion-mutated NSCLC patients post-platinum chemotherapy, with a median response duration of 11.1 months and 63% maintaining responses ≥6 months.

FDA approvals and indications

Rybrevant is approved for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC):

• With epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations in combination with lazertinib as first-line treatment 
• With EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor in combination with carboplatin and pemetrexed
• With EGFR exon 20 insertion mutations in combination with carboplatin and pemetrexed as first-line treatment
• With EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy, as a single agent.

It is not known if Rybrevant is safe and effective in children. 

Side effects

The most common side effects of Rybrevant when used in combination with lazertinib are:

• rash
• infected skin around the nail
• muscle and joint pain
• sores in the mouth
• swelling of the hands, ankles, feet, face, or all of your body
• unusual feeling in the skin (such as tingling or a crawling feeling)
• feeling very tired
• diarrhea
• constipation
• COVID-19
• dry skin
• bleeding
• decreased appetite
• itchy skin
• nausea
• changes in certain blood tests.

The most common side effects of Rybrevant when used in combination with carboplatin and pemetrexed are:

• rash
• Infected skin around the nail
• feeling very tired
• nausea
• sores in the mouth
• constipation
• swelling of the hands, ankles, feet, face, or all of your body
• decreased appetite
• muscle and joint pain
• vomiting
• COVID-19
• changes in certain blood tests.

The most common side effects of Rybrevant when used alone:

• rash
• Infected skin around the nail
• muscle and joint pain
• shortness of breath
• nausea
• feeling very tired
• swelling of the hands, ankles, feet, face, or all of your body
• sores in the mouth
• cough
• constipation
• vomiting
• changes in certain blood tests.

Your healthcare provider may temporarily stop, decrease your dose, or completely stop your treatment with Rybrevant if you have serious side effects. These are not all of the possible side effects of this medicine.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.  

Serious side effects and warnings 

Rybrevant can cause the following serious side effects:.

• Infusion-related reactions. Infusion-related reactions are common but can be severe or serious and can include life-threatening (anaphylaxis) allergic reactions. Tell your healthcare provider right away if you get any of the following symptoms during your infusion of Rybrevant:
  • shortness of breath, difficulty breathing, or wheezing
  • flushing
  • chest discomfort
  • skin rash, hives, or itching
  • swelling of your eyes, lips, or tongue
  • nausea or vomiting
  • fever
  • stomach cramps
  • chills
  • lightheadedness, dizziness, or fainting
  • numbness of the tongue, lips, cheeks, or gums
  • headache.
• Lung problems. Rybrevant may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
• Blood clot problems. Blood clots are a serious, but common side effect of Rybrevant, when given together with another drug called lazertinib, may cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that may lead to death. Your healthcare provider will start you on medicine to prevent blood clots for the first 4 months of treatment. Tell your healthcare provider right away if you have any signs and symptoms of blood clots, including swelling, pain, or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.
• Skin problems. Rybrevant can cause a severe rash, including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. You may use alcohol-free (such as isopropanol-free, ethanol-free) moisturizing cream to reduce the risk of skin problems. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may treat you with medicines or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment with Rybrevant.
• Eye problems. Rybrevant may cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems, which may include:
  • eye pain
  • changes in vision
  • inflammation of the eyelids
  • itchy eyes
  • dry eyes
  • excessive tearing
  • eye redness
  • sensitivity to light
  • blurred vision.

Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get new or worsening eye problems during treatment with Rybrevant. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.

Rybrevant may harm an unborn baby.

This is not a complete list of side effects, and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Related/similar drugs

Before receiving this medicine

Before you receive Rybrevant, tell your healthcare provider about all of your medical conditions, including if you:

• have a history of lung or breathing problems
• are pregnant or plan to become pregnant
• are breastfeeding or intend to breastfeed.

Pregnancy

Rybrevant can harm your unborn baby. Females who can become pregnant may need a pregnancy test to make sure they are not pregnant before treatment. Use birth control while using Rybrevant and for at least 3 months after your last dose. Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with Rybrevant.

Breastfeeding

It is not known if Rybrevant passes into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of Rybrevant.

How is Rybrevant administered?

Rybrevant will be given to you by your healthcare provider as an intravenous infusion into your vein.

• Your healthcare provider will decide how frequently and for how long you will receive treatment.  
• You may be given pre-medication with an antihistamine, an antipyretic, and sometimes a glucocorticoid before each dose of Rybrevant to help reduce the risk of infusion-related reactions.
• Rybrevant is often given in combination with other medicines, such as lazertinib, carboplatin, or pemetrexed.
  • If you are receiving lazertinib, you should take your dose of lazertinib by mouth anytime before your infusion with Rybrevant.
• Rybrevant is infused slowly to start with to reduce the risk of infusion-related reactions. Subsequent infusions will be quicker if you tolerate Rybrevant well.
• If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

Dosing information

Dose of Rybrevant for NSCLC in combination with lazertinib or as a single agent

Less than 80 kg:

• Weeks 1-5: 1050 mg IV
• Week 7 onwards: 1050 mg IV

Greater than or equal to 80 kg:

• Weeks 1-5: 1400 mg IV
• Week 7 onwards: 1400 mg IV

Dose of Rybrevant for NSCLC in combination with carboplatin and pemetrexed

Less than 80 kg:

• Weeks 1-4: 1400 mg IV
• Week 7 onwards: 1750 mg IV

Greater than or equal to 80 kg:

• Weeks 1-4: 1750 mg IV
• Week 7 onwards: 2100 mg IV

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your next injection.

What should I avoid while taking Rybrevant?

Rybrevant can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment. Wear protective clothing and use sunscreen during treatment. 

What other drugs will affect Rybrevant?

Other drugs may affect Rybrevant, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. No formal drug interaction studies have been conducted with Rybrevant.

Rybrevant Package Insert 

Review the Rybrevant Package Insert for more detailed information about this medicine. Discuss any medical questions with your doctor or other health care provider. This is not all the information you need to know about this medicine for safe and effective use, and it does not take the place of talking to your doctor about your treatment.

Ingredients

Active ingredient: amivantamab-vmjw
Inactive ingredients: EDTA disodium salt dihydrate, L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 80, sucrose, and water for injection.

Available as a solution in a single-dose vial for intravenous infusion of 350 mg/7 mL (50 mg/mL).

Manufacturer

Rybrevant (amivantamab-vmjw) is made by Janssen Biotech, a pharmaceutical company owned by Johnson & Johnson.

Rybrevant Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for Rybrevant.

Popular FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer